# SmartPA Criteria Proposal

| | |
|---|---|
| **Drug/Drug Class:** | Daybue Clinical Edit |
| **First Implementation Date:** | November 2, 2023 |
| **Revised Date:** | TBD |
| **Prepared for:** | MO HealthNet |
| **Prepared by:** | MO HealthNet/Conduent |
| **Criteria Status:** | ☐Existing Criteria<br>☐Revision of Existing Criteria<br>☒New Criteria |

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Daybue™ (trofinetide).

**Why Issue Selected:** On March 10, 2023, the U.S. Food and Drug Administration (FDA) approved Daybue™ (trofinetide) for the treatment of Rett Syndrome (RTT) in adults and pediatric patients two years of age and older.

RTT is a rare genetic (X-linked) neurodevelopment disorder that occurs due to a pathogenic variant in the X chromosome on the methyl CpG binding protein 2 (*MECP2*) gene. It is a spectrum disorder with a wide range of severity. Symptoms appear around the age of 18 months, followed by clinical regression between ages 1 and 4 years. The most profound changes in the child's development include central nervous system impairment, loss of expressive language, gait abnormalities, and involuntary hand movements such as hand wringing or tapping. Severe symptoms of RTT may include seizures, disordered breathing, and skeletal abnormalities. RTT affects approximately 1 in 10,00 to 15,000 live female births.

Prior to the approval of Daybue, there were no FDA-approved treatments for RTT and care focused on the management of symptoms. Daybue is a synthetic analog of glycine-proline-glutamate, and while its mechanism of action of treating RTT is unknown, it has been proposed to treat core symptoms by potentially reducing neuroinflammation and supporting synaptic function.

Due to the high cost and specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Daybue.

**Program-Specific Information:**

| Drug | Cost per bottle (WAC) | Cost per month (WAC)* | Cost per year (WAC)* |
|---|---|---|---|
| DAYBUE 200 MG/ML SOLUTION | $9,495 | $50,640 | $607,680 |

*Cost based on 27 kg participant

**Type of Criteria:**

☐ **Increased risk of ADE**
☒ **Appropriate Indications**
☐ **Preferred Drug List**
☒ **Clinical Edit**

**Data Sources:**

☐ **Only Administrative Databases**
☒ **Databases + Prescriber-Supplied**

## Setting & Population

- Drug class for review: Daybue™ (trofinetide).
- Age range: All appropriate MO HealthNet participants aged 2 years and older

## Approval Criteria

- Participant is aged ≥ 2 years **AND**
- Prescribed by or in consultation with a neurologist experienced in the management of RTT **AND**
- Diagnosis of Rett Syndrome **AND**
- Documentation of pathogenic variant in the *MECP2* gene
- Initial approval for 6 months

Continuation of Therapy

- Documentation of clinical benefit of therapy, such as slowed decline in the severity of signs and symptoms
- Continued approval for 12 months

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

| | | | |
|---|---|---|---|
| Laboratory Results: | X | Progress Notes: | X |
| MedWatch Form: | | Other: | X |

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

## Default Approval Period

3 months

## References


- Daybue [package insert]. San Diego, CA: Acadia Pharmaceuticals; March 2023
- IPD analytics. New drug review. Daybue (trofinetide). March 2023.
- ACADIA. Acadia Pharmaceuticals announces positive top-line results from the pivotal phase 3 lavender trial of trofinetide in Rett Syndrome. https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3-lavender-trial-of-trofinetide-in-rett-syndrome/
- NIH. Atypical Rett syndrome. https://rarediseases.info.nih.gov/diseases/4694/atypical-rett-syndrome